

**AMENDMENTS TO THE CLAIMS**

The listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-4 Canceled.

5. (Original) A method for treating a subject for restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty, comprising administering to said subject a composition comprising an effective amount of a lipoxin A<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty is prevented, reduced, or inhibited.

6. (Original) The method of claim 5, wherein the lipoxin A<sub>4</sub> compound is LXA<sub>4</sub> or 15-*R/S*-methyl, LXA<sub>4</sub>.

7. (Original) A method for treating a subject for restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty, comprising administering to said subject a composition comprising an effective amount of a 15-epi-lipoxin A<sub>4</sub> compound and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, such that restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty is prevented, reduced, or inhibited.

8. (Original) The method of claim 7, wherein the 15-epi-lipoxin A<sub>4</sub> compound is 15-epi-16- (*para*-fluoro)-phenoxy-lipoxin A<sub>4</sub>.

Claims 9-18 canceled.